Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 30 Issue 3
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2012  >  30(3): 197-202

GAO Yue, CHEN Anni, ZHAO Yahong, XUE Dan, AN Yongtong, CHAI Yifeng, ZHANG Hai. Experimental study on the effects of Yangxinshi tablets in the prevention and treatment of chronic ischemic heart failure and acute myocardial ischemia reperfusion injury[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 403-407,415. doi: 10.3969/j.issn.1006-0111.2016.05.006
Citation: GAO Yue, YANG Ling, WU Rong. Study on pharmacokinetics and relative bioavailability of nimodipine orally disintegrating tablet[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 197-202. doi: 10.3969/j.issn.1006-0111.2012.03.011
shu

Study on pharmacokinetics and relative bioavailability of nimodipine orally disintegrating tablet

doi: 10.3969/j.issn.1006-0111.2012.03.011

  • School of pharmacy, Second Military Medical University, Shanghai 200433,China

  • Received Date: 2010-04-14
  • Rev Recd Date: 2010-07-16
  • Objective To research the pharmacokinetics and relative bioavailability of Nimodipine rapid disintegeating tablet in human body, which was compared with Nimodipine market tablets. Methods 6 cases of health volunteer were divide into two groups randomly , alternately taking rapid disintegeating tablet A and market tablet B of Nimodipine 60mg single dosage orally, HPLC was used to determine the concentration of Nimodipine in blood. Results The main Pharmacokinetics parameters after single oral administration Nimodipine rapid disintegeating tablet A and Nimodipine market tablet B were (256.23±54.64) g/ml, (102.415±36.96) g/ml in Cmax; (0.7049±0.035) h, (1.3317±0.123) h in Tmax; (0.2734±0.031) h, (1.1958±0.141) h in T1/2; (622.77±98.03) g/(ml·h), (354.63±96.24) g/(ml·h) in AUC0 - t, respectively. The bioavailability of rapid disintegeating tablet was 177.27% relative to market tablet. Conclusion Nimodipine rapid disintegeating tablet was capable of releasing rapidly, and had an enhanced bioavailability as compared with market tablet.
  • [1] Zendelovska D,Stafilov T,Stefova M.Optimization of a solid-phase extraction method for determination of indapamide in biological fluids using high-performance liquid chromatography[J].J Chromatogr B,2003,788(1):199.
    [2] 张 莉,李 昕.RP-HPLC法测定血浆中尼莫地平浓度[J].中国药师,2004,7(11):865.
    [3] 邝荔香,丁 黎. GC法测定血浆中尼莫地平浓度及药动学研究[J].安徽医科大学学报,2000,35(3):191.
    [4] Jain DS,Subbaiah G,Sanyal M,et al.Liquid chromatography tandem mass spectrometry validated method for the estimation of indapamide in human whole blood[J].J Chromatogr B,2006,834(1):149.
    [5] Hang TJ,Zhao W,Liu J,et al.A selective HPLC method for the determination of indapamide in human whole blood:Application to a bioequivalence study in Chinese volunteers[J].J Pharm Biomed Anal,2006,40:202.
    [6] 缪海均,刘皋林,范国荣,等.尼莫地平胶丸的人体药代动力学及相对生物利用度研究[J].第二军医大学学报,2003,24(12):1371.
    [7] 梁文权. 生物药剂学与药物动力学[M]北京:人民卫生出版社,2004:266.
  • 加载中

  • Cited by

    Periodical cited type(23)

    1. 赵晓峰，邢文龙，刘红旭，尚菊菊，来晓磊，刘庆荣. 养心氏片在冠状动脉介入治疗中应用的系统评价. 中西医结合心脑血管病杂志. 2022(01): 91-94 .
    2. 周琦，邢文龙，刘红旭，尚菊菊，来晓磊，李爱勇，刘庆荣. 养心氏片治疗经皮冠状动脉介入治疗术后胸痛有效性及安全性的Meta分析. 世界中医药. 2022(06): 801-806 .
    3. 王青，卜一珊. 养心氏片联合氯吡格雷治疗冠心病心绞痛的效果观察. 中国药物滥用防治杂志. 2022(10): 1499-1502 .
    4. 唐爱，杨贵志. 养心氏片联合沙库巴曲缬沙坦钠治疗慢性老年心力衰竭患者的临床效果. 中国当代医药. 2021(15): 73-76 .
    5. 刘红旭，林谦，邢文龙. 养心氏片治疗冠心病临床应用专家共识. 中国中西医结合杂志. 2020(01): 5-13 .
    6. 刘红旭，林谦，邢文龙. 养心氏片治疗冠心病临床应用中国专家共识. 中西医结合心脑血管病杂志. 2020(02): 195-202 .
    7. 刘红旭. 《养心氏片治疗冠心病临床应用专家共识》解读. 世界中医药. 2020(04): 637-642 .
    8. Jian LI，Zhixiao WANG，Xinling ZHOU，Yihong JIANG. Advances in Research on Treatment of Heart Failure with Yangxinshi Tablet. Medicinal Plant. 2020(02): 16-20 .
    9. 谢清清，王辉，曹月娟. 养心氏片治疗心血管疾病的研究进展. 世界中医药. 2020(05): 801-804 .
    10. 范瑞云，李文阁，刘艳民，刘平，王辉. 中药养心氏片辅助治疗心功能不全临床效果对比观察. 人民军医. 2020(08): 789-792 .
    11. 范晓艳，张振伟，郭彩杰. 养心氏片联合西药标准化用药治疗PCI后反复心衰患者典型病例分析. 药学研究. 2020(11): 676-679 .
    12. 孙飞龙，袁炜婷，赵高娃，曹雅兰，向姝婷，王钰，于勤. 养心氏对慢性心力衰竭患者心功能及运动中血压和心率影响的研究. 世界中医药. 2019(04): 876-881 .
    13. 张聪，吴宗贵，薛金贵，王贤良. 养心氏片在中西医结合心脏康复中应用的中国专家共识. 中西医结合心脑血管病杂志. 2019(09): 1281-1285 .
    14. 李健，王治校，周鑫玲，姜益宏. 养心氏片治疗心力衰竭研究进展. 世界中医药. 2019(05): 1335-1338 .
    15. 李健，王治校，周鑫玲，姜益宏. 养心氏片治疗心力衰竭研究进展. 世界中医药. 2019(07): 1903-1906 .
    16. 孙飞龙，袁炜婷，胡嘉慧，于勤. 养心氏片对慢性心力衰竭病人运动耐量和生活质量的影响. 中西医结合心脑血管病杂志. 2019(17): 2581-2584 .
    17. 韩琼，韩宏毅，张艳. 心肌缺血患者再灌注损伤的临床治疗进展. 医疗装备. 2018(12): 194-195 .
    18. 郭志刚，于春霞，宋新旗. 养心氏片对心力衰竭大鼠心肌凋亡的影响. 中国老年学杂志. 2018(12): 3032-3035 .
    19. 张强，刘珂，牛红梅，张巍，马丽娟，韩继如. 养心氏片对冠心病心肌PCI术后缺血再灌注损伤的治疗效果. 云南中医学院学报. 2018(02): 15-18 .
    20. 杨凯，马尹梅，周希胜，刘文娟. 芪参益气滴丸联合养心氏片治疗慢性心力衰竭的疗效观察. 现代药物与临床. 2017(11): 2129-2132 .
    21. 姜先昭. 养心氏片治疗缺血性心肌病合并失眠的临床疗效观察. 世界中医药. 2017(07): 1538-1539+1543 .
    22. 张德芹，高学敏，张聪，陆鹏. “养心理论”构建与养心氏片组方理论探析. 中西医结合心脑血管病杂志. 2017(02): 244-247 .
    23. 张文举. 抑郁与慢性缺血性心力衰竭患者C反应蛋白的关系. 中西医结合心血管病电子杂志. 2016(25): 52-53 .

    Other cited types(5)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(5605) PDF downloads(722) Cited by(28)

Related
Proportional views

Study on pharmacokinetics and relative bioavailability of nimodipine orally disintegrating tablet

doi: 10.3969/j.issn.1006-0111.2012.03.011
  • School of pharmacy, Second Military Medical University, Shanghai 200433,China
  • Received Date: 2010-04-14
  • Rev Recd Date: 2010-07-16

Abstract: Objective To research the pharmacokinetics and relative bioavailability of Nimodipine rapid disintegeating tablet in human body, which was compared with Nimodipine market tablets. Methods 6 cases of health volunteer were divide into two groups randomly , alternately taking rapid disintegeating tablet A and market tablet B of Nimodipine 60mg single dosage orally, HPLC was used to determine the concentration of Nimodipine in blood. Results The main Pharmacokinetics parameters after single oral administration Nimodipine rapid disintegeating tablet A and Nimodipine market tablet B were (256.23±54.64) g/ml, (102.415±36.96) g/ml in Cmax; (0.7049±0.035) h, (1.3317±0.123) h in Tmax; (0.2734±0.031) h, (1.1958±0.141) h in T1/2; (622.77±98.03) g/(ml·h), (354.63±96.24) g/(ml·h) in AUC0 - t, respectively. The bioavailability of rapid disintegeating tablet was 177.27% relative to market tablet. Conclusion Nimodipine rapid disintegeating tablet was capable of releasing rapidly, and had an enhanced bioavailability as compared with market tablet.

GAO Yue, CHEN Anni, ZHAO Yahong, XUE Dan, AN Yongtong, CHAI Yifeng, ZHANG Hai. Experimental study on the effects of Yangxinshi tablets in the prevention and treatment of chronic ischemic heart failure and acute myocardial ischemia reperfusion injury[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(5): 403-407,415. doi: 10.3969/j.issn.1006-0111.2016.05.006
Citation: GAO Yue, YANG Ling, WU Rong. Study on pharmacokinetics and relative bioavailability of nimodipine orally disintegrating tablet[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 197-202. doi: 10.3969/j.issn.1006-0111.2012.03.011
shu

    HTML

Reference (7)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return